File(s) under permanent embargo
Reason: This item is currently closed access.
Prevention of rejection of allogeneic endothelial cells in a biohybrid lung by silencing HLA-class I expression
journal contribution
posted on 2019-03-15, 11:46 authored by Bettina Wiegmann, Constanca Figueiredo, Christiane Gras, Michael Pflaum, Sabrina Schmeckebier, Sotiris KorossisSotiris Korossis, Axel Haverich, Rainer BlasczykVariability in Human Leukocyte Antigens (HLA) remains a hurdle to the application of allogeneic cellular products. Due to insufficient autologous endothelial cell harvesting for the biohybrid lung, allogeneic human cord blood derived endothelial cells (HCBEC) were used for the endothelialization of poly-4-methyl-1-pentene (PMP) gas exchange membranes. Therefore, HLA class I expression was silenced stably in HCBECs to prevent rejection. The capacity of HLA class I-silenced HCBEC to abrogate allogeneic immune responses, their functional properties and suitability for endothelialization of PMP membranes were investigated. Delivery of β2-microglobulin (β2m)-specific shRNAs reduced β2m mRNA levels by up to 90% and caused a knockdown of HLA class I expression by up to 85%. HLA-silenced HCBEC abrogated T-cell responses and escaped antibody-mediated complement-dependent cytotoxicity. The EC phenotype and cytokine secretion profiles between HLA-expressing or -silenced HCBEC remained unaltered. EC specific activation (e.g. ICAM) and thrombogenic markers (e.g. thrombomodulin) remained unaffected by HLA-silencing, but their expression was upregulated by TNFα-stimulation. Furthermore, HLA-silenced HCBECs showed high proliferation rates and built an EC monolayer onto PMP membranes. This study represents a new therapeutic concept in the field of cell and organ transplantation and may bring the bioartificial lung as an alternative to lung transplantation closer to reality.
Funding
This work was partly supported by funding by the Cluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy EXC 62/1) (Unit 4.1 and 6.3), as well as by the German Center for Lung Research (DZL) (DZL: 82DZL00201), Lower Saxony Center for Biomedical Technology (NIFE) and German Research Foundation (WI 4088/1-1).
History
School
- Mechanical, Electrical and Manufacturing Engineering
Published in
BiomaterialsVolume
35Issue
28Pages
8123 - 8133Citation
WIEGMANN, B. ... et al, 2014. Prevention of rejection of allogeneic endothelial cells in a biohybrid lung by silencing HLA-class I expression. Biomaterials, 35 (28), pp.8123-8133.Publisher
© ElsevierVersion
- VoR (Version of Record)
Publisher statement
This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/Publication date
2014-06-21Notes
This paper is closed access.ISSN
0142-9612Publisher version
Language
- en